|
Real-world patient-reported and clinical outcomes of BNT162b2 mRNA COVID-19 vaccine in patients with cancer. |
|
|
Consulting or Advisory Role - MedImmune (I) |
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I) |
Travel, Accommodations, Expenses - Bayer (I); MedImmune (I); Novartis (I); PharmaMar (I) |
|
|
Consulting or Advisory Role - PledPharma |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Vertex |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech; Merck Sharp & Dohme; Oxford Immunotec |
Consulting or Advisory Role - Adagio; ADMA Biologics; Ansun Biopharma; Cidara Therapeutics; Janssen; Kyorin; Merck; Paratek; Partner Therapeutics; Pulmotect; ReViral; Shionogi; Wockhardt Pharmaceuticals; Xenex Healthcare Services |
Research Funding - Ansun Biopharma (Inst); Chimerix (Inst); Gilead Sciences (Inst); Karius (Inst); Merck (Inst); Viracor Eurofins (Inst); Xenex Healthcare Services (Inst) |
Travel, Accommodations, Expenses - Merck; Oxford Immunotec |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Guidepoint Global |
Research Funding - Guardant Health (Inst); Philips Healthcare (Inst); Tempus (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AstraZeneca; Merck; Moderna Therapeutics; Pfizer; TRACON Pharma |
Consulting or Advisory Role - Daiichi Sankyo |
Research Funding - AADi (Inst); Athenex (Inst); Novartis (Inst); TRACON Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
Hussein Abdul-Hassan Tawbi |
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Merck; Novartis |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm |
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst) |
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar |
Other Relationship - Medscape |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |